Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–49
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
has been surgically (laparoscopy or laparotomy) diagnosed with endometriosis.
has cyclic AND non-cyclic, moderate to severe endometriosis-related pelvic pain (overall pelvic pain score ≥5 using a 0-10 NRS, with 0 representing no pain and 10 representing extremely severe pain).
has had spontaneous menstrual cycles before Visit 1.
has body mass index (BMI) between 18 kg/m\^2 to 40 kg/m\^2 at Visit 1.
is not pregnant, not breastfeeding, and agrees to follow the contraceptive guidance.
must agree to switch from her usual analgesic medication to only that which is permitted in the study.
You may not be if
history of hysterectomy and/or bilateral oophorectomy.
has undiagnosed vaginal bleeding.
has chronic, non-pelvic pain not caused by endometriosis that requires chronic analgesic.
has a clinically significant gynecologic condition identified in the screening evaluation.
has a history of anaphylaxis or cutaneous adverse drug reaction (with or without systemic symptoms) to sulfonamide antibiotics or other sulfonamide-containing drugs.
has a known allergy/sensitivity or contraindication to gefapixant or its excipients.
has an allergy/sensitivity/intolerance to naproxen sodium (rescue medication) or any contraindication to its use, or has experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs).
has a history of endometriosis-related pain that was non-responsive to treatment with combined hormonal contraceptives (CHCs), gonadotropin-releasing hormone (GnRH) antagonists, GnRH agonists, progestins, or aromatase inhibitors.
has a positive urine pregnancy test at any time before randomization.
has required more than 2 weeks of continuous use of narcotics for treatment of endometriosis-related pain within 6 months of Visit 1.
Clareo Health | A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034)
